Medical stocks recently there is no market shares
Medical stocks recently there is no market shares, which need to consult the relevant information in order to answer the answer, according to years of learning experience, if the answer to the question of medical stocks recently there is no market shares, can allow you to do more with less, the following share of medical stocks recently there is no market shares related to the methodology of the experience, for you to refer to learn from.
Medical stocks recently have no market shares
Medical stocks recently have no market shares.
Medical stocks have a recent market
Medical stocks have a somewhat fluctuating market lately.
In the role of many negative factors, the medical industry sectors and individual stock trends have seen some decline. For example, Myriad Medical, Aier Ophthalmology, Changchun High-Tech, Pientzehuang, Zhifei Bio, Tiger Pharmaceuticals, Kangtai Biologicals, Hualan Bio, Renfu Pharmaceuticals, Fosun Pharmaceuticals and other weighted stocks, all of which have seen a significant drop in the recent past.
So, it can be said that there is some volatility in the recent market of medical stocks.
How have medical stocks been doing lately
Medical stocks performed relatively well at the end of the first quarter of 2023. According to the relevant data, the average price-to-earnings ratio of medical stocks was 16.51 times at the end of the first quarter of 2023, down 1.07% compared to the previous quarter but up 11.08% compared to the same period last year. Among healthcare stocks, the medical devices and services sector was the strongest performer, with an average P/E of 17.6x, while the medical devices and pharmaceuticals sector was relatively weak, with an average P/E of 15.45x.
Overall healthcare stocks performed relatively well in Q1 2023, with an average net income year-over-year growth rate of 9.92%, with the Medical Devices and Services sector being the strongest performer, with an average net income year-over-year growth rate of 17.48%, while Medical Devices and Pharmaceuticals had a relatively weak performance, with an average net income year-over-year growth rate of 5.98%.
Overall, healthcare stocks performed relatively well at the end of the first quarter of 2023, but it is important to note that price-to-earnings ratios can be affected by a variety of factors, including market sentiment and the policy environment. Therefore, investors need to analyze and make rational decisions when investing in healthcare stocks, taking into account their own risk appetite and investment objectives.
How did medical stocks fall so much recently
The recent decline in medical stocks may be due to the following reasons:
1. Overall market volatility: The recent high volatility in the market may have caused medical stocks to follow the trend and fall.
2. Valuation return of the pharmaceutical sector: after the previous rise, the valuation of the pharmaceutical sector has returned to about 30 times, which means that the upside of the pharmaceutical sector has been relatively limited. At the same time, the pharmaceutical industry has rallied nearly 40% since its low in December 2021, which may also have led to a pullback in the pharmaceutical sector.
3. Health insurance negotiation: Health insurance negotiation may affect the price of some medicines, and if the negotiation result is less than satisfactory, it may have a negative impact on related pharmaceutical stocks.
4. Epidemic control policies: Adjustments in epidemic control policies may lead to a reduction in medical demand, which will put pressure on medical stocks.
5. Earnings decline: Some medical stocks have experienced a decline in earnings, which may also be a reason for the decline in share prices.
In short, the decline of medical stocks may be affected by a variety of factors, investors need to pay attention to risk and rational investment.
What's the latest news on medical stocks
Recent news on medical stocks include:
___Innovative Medical Healthcare Co.
__ BIOTEC: Trading was light before the start of trading, now at HK$14.42, with a total market capitalization of HK$2.223 billion.
__Contact Bio: 3 people will attend the general meeting, with a combined holding of about 7,164,700 shares, or 1.14% of the total share capital. The general meeting will consider the profit distribution plan.
__Contact Bio announced that the total amount of funds planned to be invested in R&D in FY2023 is 80 million yuan to 100 million yuan. It mainly conducts research on industry trends, strengthens communication and cooperation with domestic and foreign counterparts, enhances clinical research and develops new products, and at the same time strengthens core technology research and development as well as intellectual property rights layout and improvement, and builds up core technology and international first-class research and development team in the areas of human vaccines, in-vitro diagnostic reagents and equipments, drug benefit monitoring and drug utilization monitoring, and so on.
___Contact Bio released the 2022 annual results forecast, expected 2022 annual net profit of 35 million yuan to 55 million yuan, a year-on-year decline of 80.69% to 92.53%.
Also, Bac Biological disclosed its annual report on April 12, 2023 intraday, with annual net profit of 50 million yuan to 60 million yuan in 2022, down 86.99% to 89.86% year-on-year.
Medical stocks recently there is no market stock introduction is here.